Welcome to our dedicated page for Adverum Biotechnologies news (Ticker: ADVM), a resource for investors and traders seeking the latest updates and insights on Adverum Biotechnologies stock.
Overview of Adverum Biotechnologies, Inc. (NASDAQ: ADVM)
Adverum Biotechnologies, Inc. is a U.S.-based clinical-stage gene therapy company at the forefront of developing innovative treatments for serious and rare ocular diseases. Leveraging a proprietary adeno-associated virus (AAV)-based directed evolution platform, Adverum aims to provide durable efficacy through sustained expression of therapeutic proteins. The company focuses on developing gene therapies for conditions such as alpha-1 antitrypsin (A1AT) deficiency, hereditary angioedema (HAE), and wet age-related macular degeneration (wet AMD).
Core Business and Achievements:
Adverum is advancing a robust pipeline of gene therapy product candidates. Its lead candidate, ADVM-022 (also known as Ixo-vec), is an intravitreal (IVT) injection designed to deliver long-term aflibercept levels, significantly reducing the need for frequent anti-VEGF injections in patients with wet AMD. ADVM-022 is currently being evaluated in multiple clinical trials, including the Phase 2 LUNA trial, showing promising results in maintaining vision and reducing treatment burdens.
Recent Developments:
- Leadership Appointments: In 2023, Adverum appointed Dr. C. David Nicholson and Dr. Rabia Gurses Ozden to its Board of Directors, bringing extensive pharmaceutical and clinical development expertise.
- Clinical Trials: The company reported positive preliminary efficacy and safety data from the LUNA Phase 2 trial, demonstrating significant reductions in anti-VEGF injection rates and strong safety profiles.
- Financial Growth: Adverum completed a $127.5 million private placement financing, expected to fund operations into late 2025.
Key Products and Partnerships:
Adverum’s flagship product, ADVM-022, is a gene therapy candidate for wet AMD. The company collaborates with strategic partners to enhance its research and development efforts, generating revenue through licensing, research agreements, and collaborations.
With its innovative gene therapy platform and strategic initiatives, Adverum aims to transform the standard of care for ocular diseases, preserving vision and potentially offering functional cures.
Latest News:
- November 2023: Appointment of C. David Nicholson, Ph.D., to Board of Directors.
- February 2024: Presentation of preliminary LUNA Phase 2 data at the Macula Society meeting.
- March 2024: Completion of $127.5 million private placement financing.
- April 2024: Upcoming presentation of 26-week LUNA interim analysis at the ASRS Annual Scientific Meeting.
Adverum Biotechnologies (ADVM) announced that its Compensation Committee granted inducement awards to 13 new employees on December 4, 2024. The awards include non-qualified stock options to purchase 68,640 shares and restricted stock units (RSUs) for 34,920 shares under the company's 2017 Inducement Plan.
The stock options have an exercise price of $6.00 per share, with a four-year vesting schedule: 25% vesting after one year and the remaining vesting monthly over 36 months. The RSUs will vest over three years, with 33 1/3% vesting annually, subject to continued employment.
Adverum Biotechnologies (ADVM) announced that its Compensation Committee granted an inducement award to a new employee on November 17, 2024. The award consists of non-qualified stock options to purchase 55,000 shares of common stock under the company's 2017 Inducement Plan. The stock options have an exercise price of $6.86 per share, based on the closing price on November 15, 2024. The options will vest over four years, with 25% vesting after one year and the remaining vesting monthly over 36 months, contingent on continued employment.
Adverum Biotechnologies announced positive 52-week LUNA and 4-year OPTIC trial results for Ixo-vec, their gene therapy treatment for wet AMD. The LUNA trial demonstrated that the 6E10 dose maintained visual and anatomic endpoints with over 80% reduction in injection burden. No patients using local steroid prophylaxis showed inflammation at week 52. The OPTIC trial showed stable therapeutic effects through 4 years with an 86% reduction in annual anti-VEGF injections. The company plans to advance to Phase 3 trials with the ARTEMIS study, expected to initiate in 1H 2025. Patient preference data showed 93% of LUNA participants preferred Ixo-vec over prior treatments.
Adverum Biotechnologies (Nasdaq: ADVM) announced a webcast scheduled for Monday, November 18th at 7:30 a.m. EST to present important clinical data and program updates. The company will report 52-week LUNA phase 2 clinical data and 4-year OPTIC clinical data, along with key pivotal program design elements. The webcast will include a key opinion leader panel and will be accessible through the company's investor relations website, with a replay available afterward.
Adverum Biotechnologies (NASDAQ: ADVM) reported Q3 2024 financial results and corporate updates. The company ended the quarter with $153.2 million in cash and investments, expected to fund operations into late 2025. Net loss was $27.1 million ($1.30 per share), compared to $32.9 million in Q3 2023. Research and development expenses were $20.4 million, while general and administrative expenses decreased to $9.8 million.
The company appointed Jason Mitchell as Chief Commercial Officer and remains on track to initiate its Phase 3 program in 1H 2025. Key upcoming milestones include LUNA 52-week data, OPTIC 4-year clinical data, and Phase 3 pivotal trial design updates in Q4 2024.
Adverum Biotechnologies (Nasdaq: ADVM) has appointed Jason L. Mitchell as chief commercial officer. Mitchell brings over 20 years of commercial experience, including in retinal disease and the successful launch of SYFOVRE® for geographic atrophy. He will be responsible for the launch strategy and commercial infrastructure for ixoberogene soroparvovec (Ixo-vec), Adverum's potential one-time intravitreal injection for wet age-related macular degeneration (wet AMD).
Adverum plans to announce LUNA 52-week data and pivotal program details in Q4 2024, with the Ixo-vec pivotal program set to initiate in H1 2025. The company believes Ixo-vec has demonstrated a potential best-in-class product profile, with 88% of LUNA patients preferring it over prior anti-VEGF injections. Mitchell's appointment aligns with Adverum's focus on progressing Ixo-vec toward approval and commercialization.
Adverum Biotechnologies (Nasdaq: ADVM) announced on September 5, 2024, that its Compensation Committee granted inducement awards to three new employees on September 3, 2024. The awards, granted under Adverum's 2017 Inducement Plan, include:
1. Non-qualified stock options to purchase 12,660 shares of common stock
2. Restricted stock units (RSUs) for 6,330 shares of common stock
The stock options have an exercise price of $6.76 per share, based on Adverum's closing price on September 3. They vest over four years, with 25% vesting after one year and the remainder monthly over 36 months. The RSUs vest over three years, with 33 1/3% vesting annually. Both are subject to continued employment and the terms of the 2017 Inducement Plan and award agreements.
Adverum Biotechnologies (ADVM), a clinical-stage company focused on gene therapy for ocular diseases, has announced its participation in three upcoming investor conferences:
- H.C. Wainwright 26th Annual Global Investment Conference on September 10th at 3:30 p.m. ET
- Chardan's 8th Annual Genetic Medicines Conference on October 1st at 8:00 a.m. ET
- UBS Virtual Ophthalmology Day on October 2nd at 10:30 a.m. ET
On-demand webcasts of these presentations will be available in the Investors section of Adverum's website under Events and Presentations. Replays will be accessible for at least 30 days following each event.
Adverum Biotechnologies (ADVM) reported its Q2 2024 financial results and provided updates on its Ixo-vec program for wet AMD treatment. Key highlights include:
1. Selection of 6E10 dose for Phase 3 pivotal trials based on LUNA 26-week interim analysis.
2. $173.8 million in cash and equivalents, expected to fund operations into late 2025.
3. LUNA trial showed 76% of 6E10 patients were injection-free at 26 weeks.
4. Ixo-vec received RMAT designation from FDA.
5. Q2 2024 net loss of $18.5 million, or $0.89 per share.
6. Anticipated milestones include LUNA 9-month analysis and Phase 3 trial design update in Q4 2024.
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage company focused on gene therapy for ocular diseases, has announced its participation in the H.C. Wainwright 4th Annual Ophthalmology Virtual Conference. The company's president and CEO, Laurent Fischer, M.D., will take part in a fireside chat on August 15, 2024, at 2:00 p.m. ET.
Interested parties can access the webcast of the fireside chat through the Events and Presentations section of Adverum's website, located in the Investors area. The replay of the webcast will remain available on the website for a minimum of 30 days following the presentation, allowing those unable to attend the live event to catch up on the discussion.
FAQ
What is the current stock price of Adverum Biotechnologies (ADVM)?
What is the market cap of Adverum Biotechnologies (ADVM)?
What is Adverum Biotechnologies' main focus?
What is ADVM-022?
What recent leadership changes have occurred at Adverum?
How is Adverum Biotechnologies funded?
What are the recent achievements of ADVM-022 in clinical trials?
When is Adverum's next major presentation?
What is the significance of Adverum's proprietary AAV-based platform?
How does ADVM-022 benefit patients with wet AMD?
What are the financial projections for Adverum Biotechnologies?
What are the main goals of Adverum Biotechnologies?
